Boston, MA 10/07/2013 (wallstreetpr) – The FDA approval of Duavee, a menopause drug from Pfizer Inc. (NYSE:PFE) makes a lot of business sense for this global biopharmaceutical company and its investors.
While there are already other menopause drugs in the market, PFE’s Duavee is a different one; it is devoid of the usual side effects seen in hormone replacement therapies and it is also perfect in hot-flashes reduction. Because of these attributes, the drug is expected to effectively brace the competition and emerge as the market leader in the women health segment.
The FDA approval of Duavee now means that women troubled by moderate to sever menopause effects can now gain some comfort in their lives. And this also opens up business opportunity for the manufacturing company. The drug, according to manufacturers, will also be used for prevention of post menopause osteoporosis rise. This condition has the effect of increasing fracture risk on victims.
This new menopause drug is a combination of conjugated estrogens and bazedoxifene. In this respect, it borrows a formula from PFE’s Premarin menopause drug. Duavee was developed by PFE in conjunction with Ligand Pharmaceuticals.
As a global bio-pharm and research company, PFE’s core developments have been in specialty care like oncology, nutrition, primary care, emerging markets and animal health. The company’s portfolio includes nutritional products, heath care products, small molecule vaccine, animal and human-biologic and medicines. This business has not disappointed PFE and its investors and now with development of a world-standard menopause solution, this stock is worth and investment.
PFE has a market cap of 191.99 billion. Its P/E ratio is 19.61 and it has a 52-week trading range of $31.15 high against $23.55 low. The stock closed 0.80% up at $29 on Friday.
Equities analysts are recommending the stock for buy because of its expanding market share and also growing reputation for its successful bio-pharm developments and drug-releases which capture both human and animals market.
